Delving into the Latest Updates on Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol) with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms-

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple Sclerosis

Inactive Indication-

Originator Organization

the Germans Trias i Pujol Research Institute (IGTP)

Active Organization

University of NavarraFundación Sociedad Española de Oncologia Medica

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to determine the safety and tolerability of the intranodal administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and pulsed with myelin peptides (tolDC-VitD3) in multiple sclerosis patients . To select the most appropriate regime for the development of future therapeutic trials.
To evaluate the preliminary proof of concept by clinical and/or radiological activity and immunological markers.

Start Date06 Jul 2017

Sponsor / Collaborator

Clínica Universidad de Navarra

100 Clinical Results associated with Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol)

Login to view more data

100 Translational Medicine associated with Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol)

Login to view more data

100 Patents (Medical) associated with Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol)

Login to view more data

100 Deals associated with Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol)

Login to view more data